Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.

Abstract: A chemoembolization therapy, which combines therapeutic effects of peripheral arterial occlusion with the local administration of an anti-cancer agent. A particle or microsphere occludes the arteries providing blood flow to the tumor, resulting in tumor oxygen deprivation. The anti-angiogenic agent is an anti-cancer drug.

Abstract: The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.

Abstract: At present, there is a great need for the development of new tumor pH-shiftable nanoparticles that are effective to reduce side effects, enhance active tumor focusing, improve the cellular uptake, and nuclear/cytoplasmic targeting of chemotherapy and gene therapeutic. Hence, we designed novel solid lipid nanoparticles (SLN) and liposomes (Lip) to deliver microRNA and antineoplastic agent, respectively. The designed SLN and liposomes incorporating microRNA and anticancer drugs in the core, which is surrounded by lipids modified with peptide T (a ligand plus a cell-penetrating peptide) and a nucleus-targeted sequence of peptide R as the inner shell. Moreover, coating a pH-responsive polymer (PGA-PEG) on the outer layer of Lip-TR (PGA-Lip-TR) and SLN-T (PGA-SLN-T) can protect the peptide T and R from degradation by peptidases during systemic circulation and enhance directing to the acidic tumor sites.

Abstract: In an example, the deodorant includes a solution. The solution includes a diluent and at least one fruit acid (i.e., at least one alpha hydroxy acid). The solution may also include at least one probiotic. In an embodiment, the deodorant may also include at least one applicator that is configured to hold the solution, such as at least one pad. In an embodiment, a method of using the deodorant may include contacting the armpit (e.g., axilla) or another region of the body with the deodorant to control the body odor of the individual.

Abstract: Provided is a method for preventing, alleviating or treating an ocular disease including administering a composition containing vesicles derived from Micrococcus luteus as an active ingredient wherein the vesicles are delivered to the central nervous system including the retina through the blood-brain barrier (BBB); when epithelial cells and macrophages were treated with the vesicles, not only is the secretion of an inflammatory mediator by a biological causative factor considerably inhibited, but also NLRP3 protein expression by a biological causative factor is inhibited; and when the vesicles are administered to a rabbit model with an ocular disease caused by oxidative stress, retinal degeneration is significantly inhibited, thus the vesicles derived from Micrococcus luteus can be used for a composition for preventing, alleviating or treating an age-related ocular disease and an inflammatory ocular disease, including a pharmaceutical or health functional food composition.

Abstract: Provided are vesicles derived from Faecalibacterium prausnitzii and to uses thereof. It has been experimentally confirmed by the present inventors that the vesicles in the clinical samples of patients with gastric cancer, colorectal cancer, liver cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, lymphoma, myocardial infarction, atrial fibrillation, and Parkinson's disease were significantly reduced in comparison with a normal person and that when vesicles isolated from the strain were administered, the secretion of inflammatory mediators caused by pathogenic vesicles, such as E. coli-derived vesicles, was significantly inhibited.

Abstract: A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil.

Abstract: The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.

Abstract: Termicidal compositions containing cold pressed orange oil with high concentration D-Limonene and acrylic lacquer for protective repellents against termite infestation and termiticides for the control of termites are provided. Wood preservative and protective compositions for repelling and killing wood boring insects are provided. In addition, the invention is directed to methods for repelling and killing termites by applying a pesticidally-effective amount of the above pesticidal compositions to cellulosic materials where pest control is desired.

Abstract: Injectable Ivermectin solution is safely administrable to humans and animals used the disclosed technology. A macrocyclic lactone cyclodextrin complex which is completely dissolvable or dissolved in water in a ratio of at least 10-20 milligrams of the macrocyclic lactone complex per 5 milliliters of water. The macrocyclic lactone cyclodextrin complex is non-toxic, without using organic solvents, and in embodiments, formed by adding a surfactant to the macrocyclic lactone complex to water. The macrocyclic lactone cyclodextrin complex is Ivermectin or an Ivermectin derivative in some embodiments. The cyclodextrin complex is 2-hydroxypropyl-beta-cyclodextrin in some embodiments of the disclosed technology. The surfactant can be polysorbate 80 and is in a ratio of 0.01% to 25%, by weight, to said water. The water soluble complexes can be added to the water. The water-soluble complexes can have at least one of an anti-parasitic, anti-viral and anti-cancer complex.

Abstract: Zeolites for extraction of heavy metals are given enhanced purification in a first method stage and further processed in a second method stage to form liquid and solid phases including swollen clinoptilolite fragments ranging from 200 to 2000 Daltons and formed as liposomes and usable to substantially reduce heavy metal ppm burdens for purposes of safe ingestion by mammals and reduction of heavy metal contaminants of gut, vascular and lymphatic systems of a mammalian host.

Abstract: Composition for lightening keratin fibers, comprising: at least 20% weight of fatty substances free of carboxylic acid groups relative to the total weight of the composition, at least one alkalizing agent, at least one surfactant, and at least one oxidizing agent, wherein the concentration of oxidizing agent in the composition is from 1.5% to 2.5% by weight relative to the total weight of the composition.

Abstract: Provided herein are methods for the prevention and treatment of cardiovascular diseases and disorders in a subject diagnosed as having suffered a cerebrovascular injury by administering agents that contain or induce the expression of microRNA-126.

Abstract: A composition for reducing microbial activity in an environment susceptible to microbial activity, comprising: metallic nanoparticles; and an oxygenation agent.

Abstract: The present invention is related to polymer based formulation for release of drugs and bioactives at gastrointestinal tract specific sites including stomach, intestine and colon.

Abstract: The composition for bone regeneration, comprises a) a first phase (3) comprising a plurality of cross-linked hydrogel chunks (1) having a mean diameter of less than 1000 ?m and incorporating an amount of mineral particles (2); and b) a second phase (4) comprising a physiologically-compatible aqueous liquid acting as a carrier for the chunks; the chunks being embedded in the second phase (4). The mineral particles (2) have a mean diameter of less than 10 ?m and the amount of the mineral particles (2) is less than 20 weight-% of the first phase.

Abstract: In certain aspects, the present disclosure provides methods and materials for the treatment of cancer. In accordance with some forms, the disclosure provides methods for the treatment of cancer which include inhibition of ubiquitin carboxyl-terminal hydrolase.

Abstract: A lipid membrane structure includes, as lipid components, a lipid compound represented by Formula (I): (R1)(R2)C(OH)—(CH3)a—(O—CO)b—X??(I) [in the formula, a represents an integer of 3 to 5; b represents an integer of 0 or 1; R1 and R2 each independently represents a linear hydrocarbon group that may have —CO—O—; and X represents a 5- to 7-membered non-aromatic heterocyclic group or a group represented by Formula (B) (in the formula, d represents an integer of 0 to 3, and R3 and R4 each independently represents a C1-4 alkyl group or a C2-4 alkenyl group, where, R3 and R4 may be bonded to each other to form a 5- to 7-membered non-aromatic heterocycle (where, one or two C1-4 alkyl groups or C2-4 alkenyl groups may be substituted on the ring)].

Abstract: The present disclosure relates generally to oral compositions and methods for freshening breath and oral cleansing, and more particularly, to oral compositions comprising a combination of an extract of magnolia and a hydrocarbon. The oral compositions are useful for improving oral health, including freshening breath and reducing the adherence of plaque to teeth.